Skip to main content
SpringerLink
Log in

Contemporary outcomes of high risk relapsed refractory classical hodgkin lymphoma patients—role of maintenance therapy in the real world

  • Correspondence
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Outcome post autologous HSCT relapsed or refractory classical Hodgkin lymphoma.

References

  1. Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the american society for blood and marrow transplantation. Biol Blood Marrow Transpl. 2015;21:1863–9.

    Article  Google Scholar 

  2. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–71.

    Article  CAS  PubMed  Google Scholar 

  3. Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy. Haematologica. 2012;97:1073–9.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119:1665–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639–42.

    Article  CAS  PubMed  Google Scholar 

  6. Hahn T, McCarthy PL, Carreras J, Zhang MJ, Lazarus HM, Laport GG, et al. Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma. Biol Blood Marrow Transpl. 2013;19:1740–4.

    Article  Google Scholar 

  7. Damlaj M, Ghazi S, Syed G, Pasha T, Gmati G, Salama H, et al. Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transpl. 2017;52:1342–4.

    Article  CAS  Google Scholar 

  8. Schot BW, Zijlstra JM, Sluiter WJ, van Imhoff GW, Pruim J, Vaalburg W, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood. 2007;109:486–91.

    Article  CAS  PubMed  Google Scholar 

  9. Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134:22–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology & HSCT, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia

    Moussab Damlaj, Bader Alahmari, Husam AlSadi, Mazin Ahmed, Zied AlJubour, Ayman Alhejazi, Hend Salama, Ayman Ibrahim, Abdulrahman Al Raizah, Mohammed Bakkar, Abdulraouf Ghori, Ahmed Alaskar & Mohsen Alzahrani

  2. College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

    Moussab Damlaj, Bader Alahmari, Ayman Alhejazi, Hend Salama, Ayman Ibrahim, Abdulrahman Al Raizah, Mohammed Bakkar, Abdullah S. Al Saleh, Ahmed Alaskar & Mohsen Alzahrani

  3. King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

    Moussab Damlaj, Bader Alahmari, Ayman Alhejazi, Hend Salama, Ayman Ibrahim, Abdulrahman Al Raizah, Mohammed Bakkar, Abdullah S. Al Saleh, Ahmed Alaskar & Mohsen Alzahrani

  4. Sheikh Shakhbout Medical City, Abu Dhabi, UAE

    Moussab Damlaj

  5. Khalifa University, Abu Dhabi, UAE

    Moussab Damlaj

  6. Alfaisal University, Riyadh, Saudi Arabia

    Mohamed Tlayjeh

  7. American University of Beirut, Beirut, Lebanon

    Ahmad Damlaj

Authors
  1. Moussab Damlaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohamed Tlayjeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmad Damlaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bader Alahmari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Husam AlSadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mazin Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zied AlJubour
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ayman Alhejazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hend Salama
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ayman Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Abdulrahman Al Raizah
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Mohammed Bakkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Abdulraouf Ghori
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Abdullah S. Al Saleh
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Ahmed Alaskar
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Mohsen Alzahrani
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MD: Designed the study, collected the data, analyzed the data and wrote the paper. MT, AD: Designed the study and wrote the paper. BA, HA, MA, ZA, AA, HS, AI, AAR, MB, AG, ASA, AA, MA: Designed the study, provided study subjects and wrote the paper.

Corresponding author

Correspondence to Moussab Damlaj.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Damlaj, M., Tlayjeh, M., Damlaj, A. et al. Contemporary outcomes of high risk relapsed refractory classical hodgkin lymphoma patients—role of maintenance therapy in the real world. Bone Marrow Transplant 58, 1160–1162 (2023). https://doi.org/10.1038/s41409-023-02036-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-023-02036-x

  • Springer Nature Limited

Search

Navigation